The development of neutralizing antibodies (NAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be …

Background Understanding the longitudinal trajectory of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) antibodies is crucial for diagnosis of prior infection and …

Objective The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
challenges national health systems and the global economy. Monitoring of infection rates …

Passive transfer of antibodies from COVID-19 convalescent patients is being used as an
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …

Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …

Background There is a need for validated and standardized severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and …

BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …

Abstract Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no
licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal …

Background The association between SARS-CoV-2 commercial serological assays and
virus neutralization test (VNT) has been poorly explored in mild patients with COVID-19 …

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore,
a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently …